# ANAND M. BOKARE, *M. Pharm, PhD, MBA*

**Mobile:** 91-9765260872
**E-mail**: bokareanand@gmail.com
*B-503, Sai Aashirwad society Behind pashankar auto, Sus road, Baner, Pune 411045*


## ❖ Professional Summary:

Highly motivated scientist with 17+ years of Pharmaceutical research experience ranges from Drug Discovery and Development to the regulatory approval process in the Pharma Industry (innovation to non-clinical studies to regulatory filing). Involved in a number of due diligence analyses.

Prepared an effective and scalable strategy to achieve the business objective through evaluation and analysis of new drug targets (market research), novelty, competitive strategy (competitive intelligence), feasibility, value selling, and relationship management. Budgeting and forecasting for in-department. Planning, executing, and maintenance of ongoing plans and future strategies for competitive growth.

Integrated communication with leaders of Lupin as well as an international expert panel from outside for their expert opinion on new drug development, market potential, and collaborations.

Focus on business planning, customer management, sales strategy, relationship building, and Partner Management

Key contributor in 7 INDs and in out-licensed deals of Lupin's anticancer molecules, Suven's CNS molecule and Ranbaxy's asthma molecule. Detail-oriented professional who works well in a team environment with proven track record and problem-solving capability. Excellent communication and interpersonal skills with demonstrated ability for leadership.

Work done to date, has led to 5 publications in internationally acclaimed peer reviewed journals and 7 poster in different international conferences

## ❖ Professional Skills:

➢ Medical and Scientific Information

- Literature Review and providing scientific inputs to the and clinical department for advancing projects.
- Understanding of competitor and pipeline literature for disease states of relevance to the company.
- Updating clinical trial milestone and patent update for ongoing projects to internally.
- Scientific literature search -To extract, analyze and collate data from various clinical/toxicology/efficacy related databases like TOXNET, PubMed, ScienceDirect etc.

- Data base preparation of pre-defined disease area, with respect to priority and importance of disease/indication in the major markets, epidemiological and economic burden of the disease.
- Critical analysis and interpretation of information from a multitude of disparate data sources including clinical trial registries, Pubmed, Medline etc.,
- Responding to complex external and internal medical information inquiries in compliance with regulations and company SOPs/guideline.
- Giving formal and information presentations regarding different therapeutic areas, both internally and externally.
- Develop and maintain necessary templates, formats and styles to ensure that documents generated meet industry, internal, and client requirements.
- Disseminate and convey complex medical and scientific information to professional and internal audiences.
- Knowledge of statistical data analysis tool Graph pad prism and hand on experience of application of various statistical analysis of data.
- Experienced on managing research and scientific education activities.
- Strong background in data compilation, statistical data analysis and recording in electronic note book.
- Sound knowledge of ICH, GCP and GLP guidelines.
- Attended medical conferences in order to scholarship understand the current & future state of science learning and medicine in relevant therapeutic area(s).

➢ <u>Drug Development:</u>

- Good Knowledge of Pharmaceutical Research and Development with comfortable working knowledge of Drug Discovery and Development.
- Reviews and evaluation of pharmacological studies, toxicological studies, pharmacokinetic studies submitted in support of INDs, amendments, supplements, and reports to new drug applications to assess the safety of the drug based on experiments.
- Product evaluation in Oncology, Immuno-oncology, COPD and CNS.
- Strategy for novel drug development in therapeutic areas i.e., oncology CNS, asthma and COPD.
- Experience of working in cross-functional teams like formulation, pharmacokinetic and quality assurance team in of Pharmaceutical Research and Development.
- Coordinate and monitoring regulatory studies to ensure GLP like compliance.

➢ <u>Project Management:</u>

- Initiate and develop project plans for new/additional services on assigned project.
- Prepare project plans and associated budgets for projects and providing updates on project status to senior management/ client.
- Determine the resources required to complete the project.

- Execute the project according to the project plan/timelines.
- Collaborate with internal stakeholders/ other departments (e.g., Analytical, Formulation, HR, IT, Admin, Maintenance etc.) for required resources/ services.
- Evaluate & implement alternative solutions for successful execution in a cost-effective manner.
- Prepare weekly/monthly reports, agendas, meeting minutes and presentations.
- Manage Project review meetings and ensure proper conduct during those meetings.
- Update project status to team, senior management/ client.
- Project prioritization in line with the organizational goals and objectives.
- Manages relationships with vendors and other external partners including managing all outsourcing, purchasing of chemicals, biological reagents and instruments.
- Participate in the design, writing and review of all project-related documents.
- Update SharePoint to document project activities, timeline & tasks, project team members, etc.
- Resolve queries and issues of sites and with vendors.
- Interacting with various functional teams/departments for tracking the progress of the projects

❖ **Occupational Contour:**

➢ **Job Responsibilities**

**Lupin Ltd. (Research Park), Pune** **Principal Scientist June 2010 to Oct 2022**

- Leading a group of scientists on development of orally efficacious small molecule therapeutics for cancer.
- Performed extensive market research, presented the rationale and subsequently explored the potential of a novel therapeutic target(s) for oncology and CNS.
- Conducted all the relevant “IND-enabling” studies for the selected anticancer lead molecule.
- Initiated novel in vivo models to provide a USP (Unique Selling Point) for the lead compound as compared to the competitor molecule.
- Execution and supervision of in vivo assays to study the efficacy of small molecules in various xenografts models.
- Developing clinically relevant models for testing in vivo efficacy
- Providing scientific leadership and guidance in trouble-shooting complex problems during assay development and screening.
- Interacting with numerous internal groups including Medicinal Chemistry, DMPK, and Molecular Biology for conducting studies, managing internal resource needs, and coordinating timely delivery of quality data.
- Interacting with group leaders in other therapeutic areas to develop cross-therapeutic area strategies for resources (instrumentation and personnel).

- Helps to identify relevant models and works within team to establish work plan for in vivo PK/PD and pharmacology support
- Development and validation of in-vivo models for cancer (orthotropic, allograft and xenograft models) cognitive impairment, asthma, COPD and cerebral stroke (tMCAo and pdMCAo)
- Conducted and delivered presentation learnings and development programs through CONQUER (Challenges Opportunity and novel quest in Oncology) and DIOL platform at Lupin
- Prepare, review and deliver scientific presentations for internal/external audience
- Scientific insights from conferences/congresses around the globe, routinely summarize clinical/pre-clinical studies and prepare publication decks for internal/external engagements at scientific platforms.
- Team Lead - (in vivo) for MALT1 Program: Lupin ties up with US-based AbbVie for a cancer drug, to earn approx. $ 1 billion.
- Team Lead: Non-clinical activity for LND101001. “A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer’s Disease” European Union Clinical Trials Register:

**Ranbaxy Research Lab. Ltd, Gurgaon, Haryana Research Scientist Sep 2008 to June 2010**

---

- Involved in Asthma & COPD project from basic research to candidate nomination to IND studies
- Involved in understanding the scientific need of costumer and present them the capabilities of core scientific team to the stake holder
- Part of team involved in budgeting, costing of pre-clinical projects for sponsors.
- Act as one point contacts for particular sponsors for their project updates and issues.
- Responsible for Drafting study protocol and reports for various non-clinical efficacy studies in therapeutic area like Asthma & COPD
- Worked as Study for different studies
- Work with relevant managers to devise “fit-for-purpose” nonclinical plans and manage Execution of strategy
- Manage the tactical implementation of nonclinical studies (Work Statements, Protocols, Study Reports)
- Writing preclinical IB reports, SOPs, study protocols , IAEC protocols
- Experienced in writing Investigating Brochures, IND submission documents and led skilful presentations of scientific data before stakeholders in various scientific forums.

**Suven Life Sciences Ltd Hyderabad** **Research Associate** **Dec 2005 to Sep 2008**

- Involvement in Investigational New Drug Application submission SUVN-502 (Phase-II)
- Involved in abstract writing for different conferences SFN, IBRO, AAPS, ICAD
- One of the key members involved in collaborative project between Suven Life Sciences and Eli Lilly and Company.
- Participation in due-diligence programmers in relation to the development candidates
- Identification and evaluation of novel targets for CNS disorders
- Development and validation of in-vivo models for cognitive impairment
- Tested NCEs in core battery safety pharmacological studies (CNS, CVS and respiratory system), secondary safety pharmacological (Gastrointestinal system and Renal safety study) kaolin food intake and CTA safety study
- Experience in working with various biological matrices (plasma, cerebrospinal fluid, urine, feces, tissues and tumors)
- Experience of various surgical techniques like cannulation of jugular vein and carotid artery in rodents, orthotropic xenografts, stereotaxic injections, Guide cannula implantation, administration of drugs into various brain regions

## ❖ Honors & Awards:

- Selected and completed the PhD (2014-2018) via advance studies for capability enhancement (ASCENT) program at Lupin research Park Pune
- Received "Bravo Award" in 2015, 2016 and 2017 at Lupin Ltd., for consistence extraordinary performance
- Received Suresh kare foundation scholarship for M. Pharm project

## ❖ List of Publications and Posters:

1. **Bokare AM**, Praveenkumar AK, Bhonde M, Nayak Y, Pal R, Goel R., 5-HT6 Receptor Agonist and Antagonist Against β-Amyloid-Peptide-Induced Neurotoxicity in PC-12 Cells. Neurochem Res. 2017;42(5):1571-1579.
2. **Bokare AM,** Bhonde M, Goel R, Nayak Y. 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats . Psychopharmacology (Berl). 2018 May;235(5):1557-1570
3. Verma MK, Goel RN, **Bokare AM** ..et al, LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization. Eur J Pharmacol. 2021 Jan 15; 891:173685.
4. Sinha N, Karche NP.., **Bokare AM..**et al. Discovery of novel, potent, brain-permeable and orally efficacious positive allosteric modulator of alpha 7 nicotinic acetylcholine receptor[4-(5-(4-chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide],

structure activity relationship and preclinical characterization. J Med Chem. 2020 Feb 13;63(3):944-960.

5. Shukla MR, Patra S.. **Bokare A**..et al. Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4Hquinolizin-2-l)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models.J Med Chem. 2020 Dec 10;63(23):14700-1472
6. Mahip K Verma , Charudatt Samant..**Anand M Bokare** et al. PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282. Biochem Biophys Res Commun. 2022 Nov 15;637:267-275.
7. P: Effect of cholinesterase inhibitor in cued and non- cued version of the working memory *R. Abraham, S. Vishwakarma, P. Jayarajan, **A. Bokare**, R. Nirogi; Neuroscience 2007.
8. P: Cognitive enhancement with Olanzapine – Increase in acetylcholine may not be solely responsible – A Morris water maze and microdialysis study in rats, *V. Kandikere, S. Vishwakarma, V. Benade, P. jayarajan, R. Saralaya, **A. Bokare**, N. Muddanna, R. Abraham, G. Bhyrapuneni, K. Mudigonda, R. Nirogi; Neuroscience 2007.
9. P: SUVN-502 A potent 5-HT receptor antagonist reverses MK-801 induced amnesia and enhances brain glutamate levels, *S. Vishwakarma, V. Benade, V. Marshal, P. Jayarajan, **A. Bokare**, R. Abraham, R. Saralaya, N. Muddanna, G. Bhyrapuneni, K. Mudigonda V. Kandikere, Nirogi; Neuroscience 2007. \
10. P: SUVN-507 and its active metabolite in animal models of senile dementia,*P. Jayarajan S.Vishwakarma, R. Abraham, **A. Bokare**, M. Dokania, Nirogi; Neuroscience 2007.
11. P: Effect of age of laboratory rodents on neurological experiments, *R. Abraham, P. Jayarajan, M. Dokania, **A. Bokare**, F. Khan R. Nirogi; Neuroscience 2008.
12. P: 5-HT6 antagonist in animal models of feeding behavior ***A. Bokare**, D. Shanmuganathan, P. Jayarajan, V. Marshal, R. Nirogi; Neuroscience 2008.
13. P: Effect of SUVN-502 in animal models of working memory, *R.V. Nirogi, R. Abraham, **A. Bokare**, P. Jayarajan, M.K. Dokania, D. Shanmuganathan, V. Marshal: Neuroscience 2008.

## ❖ Conference Attended:

- 21st ISCB International Conference (ISCBC-2015) on "Current Trends in Drug Discovery and Developments (CTDDD)", 25th -28th Feb, 2015 at CDRI Lucknow, India.

- Frontiers in Oncology: Genetics, Diagnostics and Therapeutics: Global Cancer Summit, organized by the BioGenesis from 18th -20th November 2015 at the J.N. Tata Auditorium Indian Institute of Sciences Bengaluru, India
- International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders" Society for Neurochemistry, India (SNCI) 21 -23 February, 2013
- International Conference on Neurodevelopment and Neurological diseases organized by Tata Institute of Fundamental Research, Mumbai from 11-14 January 2012
- International symposium on Metaloic signaling in brain in health and disease by society for Neurochemistry, India from Jan 7-9, 2011 at the Hyderabad University, Hyderabad, India

## ❖ Educational Background:

| | |
|---|---|
| **2014 – 2018** | **PhD in Pharmaceutical Sciences (Lupin sponsored)**<br>Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, INDIA<br>Thesis Project: A Study on The Role of Central 5-Ht6 Receptors in Memory Impairment Associated With Neurodegeneration.<br>Enrolled for Lupin sponsored PhD in July 2014. Successfully completed the Research Methodology course. Thesis was submitted in June 2018 and degree was awarded on Oct 2018. |
| **2011- 2013** | **Master of Business Administration**<br>Yashwantrao Chavan Maharashtra Open University (YCMOU) Nashik. |
| **2003 – 2005** | **Master of Pharmacy (Pharmacology)**<br>Padm. Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune (M.S.) - Pune University. |
| **1999 – 2003** | **Bachelor of Pharmacy**<br>Rajgad Dnyanpeeth's College of Pharmacy, Bhor, Pune (M.S.)-Pune University |

## ❖ Professional Membership:

- Life member of Society for Neurochemistry, India
- Nominated as a Board of study member at Sanjay Ghodawat University Kolhapur.